Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [3][9]. Core Insights - The company is positioned as a tungsten industry operation management platform under China Minmetals, with a comprehensive business layout covering the entire tungsten industry chain [4][20]. - Revenue has been steadily increasing, driven by the injection of high-quality mining assets, which has enhanced the company's profitability [5][29]. - The supply of tungsten concentrate is expected to tighten in the long term, while emerging sectors are likely to drive demand for hard alloys upward [6][44]. - The company is gradually injecting high-quality tungsten mining assets, benefiting from the rapid development of AI-related PCB micro-drill business [7][29]. - The investment suggestion indicates that tungsten prices are expected to remain strong due to long-term supply constraints and growing demand, with projected revenues and net profits showing significant growth from 2025 to 2027 [8][9]. Summary by Sections Company Overview - The company was established in 1991 and became a controlled entity of China Minmetals in 2010, evolving into a comprehensive tungsten industry platform [4][20]. - Its main business segments include cutting tools, hard alloys, refractory metals, concentrate and powder products, and trade and equipment [24][25]. Revenue and Profitability - The company has shown steady revenue growth, with a compound annual growth rate (CAGR) of 17.39% from 2019 to 2022, and net profit CAGR of 63.24% during the same period [29]. - In 2024, revenue is expected to grow by 7.8% year-on-year, with net profit increasing by 17.47% [29][31]. Supply and Demand Dynamics - Tungsten is a strategic rare metal with limited global supply, and China holds a dominant position in tungsten reserves [6][49]. - The demand for hard alloys is expected to rise due to emerging applications in various high-tech sectors, including AI and renewable energy [6][44]. Asset Injection and Business Expansion - The company is in the process of acquiring high-quality tungsten mining assets, which is anticipated to significantly enhance its performance [7][21]. - The PCB micro-drill business is expected to benefit from the rapid growth in AI applications, with plans for increased investment in this area [7][8]. Financial Projections - Projected revenues for 2025, 2026, and 2027 are expected to be 175.97 billion, 196.59 billion, and 210.98 billion respectively, with corresponding net profits of 12.47 billion, 17.84 billion, and 21.56 billion [9][11].

Group 1: Core Insights - The report highlights that Miaokelando has solidified its leading position in the cheese market through strategic partnerships, particularly with Mengniu, and has maintained a market share exceeding 35% in cheese sales in China as of 2023 [2][6] - The company has focused on a "cheese-centric" strategy, expanding its product matrix to include ready-to-eat nutrition, family dining, and food service industries, with nearly 100 SKUs [3][5] - The report indicates that the cheese market in China is in a growth phase, with a low penetration rate of less than 3% compared to the overall dairy market, suggesting significant room for growth [6] Group 2: Financial Performance - Miaokelando's revenue for 2024 is projected to be 1.313 billion yuan, reflecting a year-on-year growth of 14.07%, with cheese sales volume reaching 80,300 tons, a 39.39% increase [5][7] - The company is expected to achieve revenues of 5.435 billion, 6.193 billion, and 7.100 billion yuan for the years 2025 to 2027, with corresponding year-on-year growth rates of 12.22%, 13.94%, and 14.64% [7] - The net profit attributable to the parent company is forecasted to be 241 million, 357 million, and 471 million yuan for the same period, with significant growth rates of 112.10%, 48.20%, and 31.86% respectively [7]

Investment Rating - The report gives the company a "Buy" rating for the first coverage [7]. Core Insights - The company has solidified its leading position in the Chinese frozen food industry with a market share of 6.6% as of 2024, ranking first overall and significantly leading in specific segments such as frozen prepared foods and frozen dishes [2][17]. - The company is shifting from a "channel-driven" approach to a "new product-driven" strategy, expanding into the frozen baking sector through acquisitions, which is expected to create a second growth curve [5][16]. - The domestic frozen food market is characterized by low concentration and high growth potential, with a projected compound annual growth rate (CAGR) of 9.4% from 2024 to 2029, driven by increasing consumer demand and low per capita consumption compared to mature markets [4][46]. Summary by Sections Company Overview - The company was founded in 2001 and has established a nationwide marketing network, with significant strategic initiatives since its IPO in 2017, including entering the frozen dish market and expanding its product offerings through acquisitions [15][18]. - The company has developed a diverse product matrix with over 500 products, focusing on frozen prepared foods, frozen dishes, and frozen noodle products, maintaining a strong market position in each category [21][24]. Industry Analysis - The global frozen food market is expanding, with a projected size of $417.7 billion in 2024 and a CAGR of approximately 6.0% from 2024 to 2029, with Asia leading the growth at 7.8% [3][39]. - China's frozen food market is the second largest globally, with a market size of approximately $31.4 billion in 2024 and a low concentration ratio (CR5) of 15%, indicating significant consolidation opportunities [4][41]. - Emerging markets like Southeast Asia are expected to grow rapidly, with a projected CAGR of 14.0% from 2024 to 2029, driven by demographic trends and changing consumer habits [4][46]. Financial Forecast and Investment Recommendations - The company is expected to achieve revenues of 158.36 billion, 169.68 billion, and 184.38 billion yuan for the years 2025 to 2027, with year-on-year growth rates of 4.69%, 7.15%, and 8.66% respectively [5][69]. - The net profit attributable to the parent company is forecasted to be 14.15 billion, 15.66 billion, and 17.50 billion yuan for the same period, with growth rates of -4.73%, 10.73%, and 11.74% respectively [5][69].

Industry Overview - The securities industry has shown a positive performance with non-bank and brokerage indices leading the gains, while valuations remain low [2] - The brokerage index has increased by 1% this week, outperforming the CSI 300 index by 1.3 percentage points, with a price-to-book (PB) ratio of 1.38x, which is at the 35th percentile of the past decade [2][3] - The top five performing brokerages this week include Dongxing Securities (+9.6%), Huatai Securities (+3.5%), and GF Securities (+3.3%), while the largest declines were seen in Hongta Securities (-1.4%) and Zhongtai Securities (-1.6%) [2] Market Data - The average daily stock trading volume in the Shanghai and Shenzhen markets decreased to 17,410 billion yuan, a 10.1% week-on-week decline [3] - For December, the average daily trading volume is 17,870 billion yuan, reflecting a year-on-year increase of 12.2% but a month-on-month decrease of 5.8% [3] - The total equity financing this week reached 9.9 billion yuan, with an increase of 137% week-on-week, driven by a significant rise in IPO activities [4] Investment Recommendations - The brokerage industry's performance is expected to continue recovering, benefiting from long-term capital inflows and international business opportunities, providing support for mid-to-long-term earnings [5] - The current PB ratio indicates a high margin of safety for the brokerage sector, suggesting opportunities for left-side positioning [5] - Recommendations include focusing on internet brokerages with strong beta attributes, such as Zhina Compass, and considering Jiufang Zhitu Holdings in the Hong Kong market due to its strong earnings certainty [5]

Investment Rating - The industry rating is maintained at "Overweight" [2] Core Insights - The retail sector saw a slight increase of 0.16% last week, closing at 2462.73 points, ranking 24th among Shenwan's primary industries, underperforming the CSI 300 index by 1.79 percentage points [2][7] - The current Price-to-Earnings (PE) ratio for the retail sector is 52.17X, with a Price-to-Book (PB) ratio of 2.09X, indicating a slight increase in valuation metrics compared to the previous week [3][16][17] - In November, the total retail sales of consumer goods reached 43,763 billion yuan, growing by 3.0% year-on-year, with a year-to-date growth of 3.5% [4][19] - The offline retail landscape showed varied performance, with convenience stores and supermarkets leading growth, while department stores and specialty stores lagged [4][20] Summary by Sections Industry Performance - The retail sector's performance over the last month shows a relative return of 2.8%, a 3-month return of 6.0%, but a 12-month decline of 9.3% [2] - The sector's absolute returns were 5.7% over the last month, 7.4% over the last three months, and 7.7% over the last year [2] Valuation Metrics - The PE ratio for the retail sector is currently at 52.17X, with a maximum of 52.76X and a minimum of 31.27X over the past year [3][16] - The PB ratio stands at 2.09X, with a maximum of 2.12X and a minimum of 1.52X in the last year [3][17] Industry Dynamics - The November retail sales data indicates a 2.8% year-on-year growth in goods retail, with dining revenue increasing by 4.0% [4][19] - Online retail sales grew by 9.1% year-on-year, significantly outpacing the overall retail sales growth [20] Investment Recommendations - The report suggests maintaining an "Overweight" rating for the retail sector, highlighting opportunities in offline chain supermarkets, high-end domestic beauty brands, and sectors related to emotional consumption [5][21][23]

Investment Rating - The industry rating for the medical consumables sector is "Overweight" (maintained) [2][5] Core Insights - The medical consumables sector saw a slight increase of 0.08% last week, while the broader pharmaceutical and biological sector decreased by 0.18% [2][4] - The current Price-to-Earnings (PE) ratio for the medical consumables sector is 35.44X, with a Price-to-Book (PB) ratio of 2.55X, indicating a slight increase in valuation metrics compared to the previous week [3][14][16] - The sixth batch of national high-value medical consumables procurement has officially started, with a focus on optimizing selection rules to ensure long-term stability in the industry [4][17] Industry Dynamics and Key Announcements - The sixth batch of national procurement for high-value medical consumables was launched on December 22, 2025, with specific demand quantities for various products outlined [4][17] - The procurement aims to provide opportunities for domestic products to gain market share and replace imports, particularly in drug-coated balloons and urological intervention consumables [4][19] Investment Recommendations - The report suggests focusing on leading companies with strong cost control and innovation capabilities, particularly in high-value consumables such as interventional and electrophysiological products [5][21] - Companies like Microelectrophysiology and Maipu Medical are highlighted for their rich product lines and high innovation levels, while companies like Weigao Orthopedics are noted for their improving performance [5][21]

Macro Environment Outlook - The global economy is in a recovery phase but remains uncertain, with the IMF predicting a decline in global economic growth from 3.2% in 2025 to 3.1% in 2026 [15] - Developed economies are expected to maintain a growth rate of 1.6% in 2026, while emerging markets and developing countries will see a decrease from 4.2% to 4.0% [15] - China's economic growth is projected to slow from 4.8% in 2025 to 4.2% in 2026, reflecting a broader trend of economic deceleration [15] Equity Market Outlook - The equity market is anticipated to exhibit a "slow bull" structure in 2026, characterized by interwoven themes of technological growth, anti-involution, consumption, and low-volatility dividends [6][49] - Long-term capital is expected to continue entering the market, with liquidity remaining moderately loose for most of the time [6][49] - The A-share market has shown a steady upward trend in 2025, with significant contributions from the technology sector and policies promoting cyclical stocks [40][41] Bond Market Outlook - The bond market is expected to maintain a volatile pattern in 2026, with limited downward space for yields, particularly in the 10-year government bond yield projected to fluctuate between 2.0% and 1.5% [6][7] - The overall economic fundamentals are not expected to improve significantly in the short term, limiting the upward pressure on interest rates [6][7] - Investment strategies in the bond market should shift from "buy and hold" to trading to capture short-term opportunities [6][7] Commodity Market Outlook - The outlook for commodities in 2026 remains positive, particularly for gold and copper, driven by expectations of a shift in U.S. monetary policy and a global central bank gold-buying trend [6][7] - The anticipated weakening of the U.S. dollar is also expected to benefit emerging market assets [20] Investment Strategy - The recommended asset allocation for 2026 prioritizes equities over commodities, followed by bonds and cash [6][7] - The report suggests that insurance capital will continue to increase its equity investments, with an estimated inflow of around 2 trillion yuan into the A-share market in 2026 [49][50]

证券研究报告 2025 年 12 月 25 日 湘财证券研究所 行业研究 食品饮料行业点评 深加工是中国乳业的发展方向 ——对欧盟乳制品征收反补贴政策点评 相关研究： | 1.《品类创新扬帆，穿越液奶周期 | | | --- | --- | | ——伊利股份2026年经销商大会 | | | 点评》 | 2025.12.19 | | 2.《妙可蓝多：品牌破圈，国产替 | | | 代加速》 | 2025.11.28 | | 3.《板块情绪回暖，估值极具性价 | | | 比》 | 2025.11.24 | 行业评级：买入（维持） 近十二个月行业表现 % 1 个月 3 个月 12 个月 | 相对收益 | -3.8% | 0.3% | -22.9% | | --- | --- | --- | --- | | 绝对收益 | 4.4% | 1.4% | -13.7% | | | | 注：相对收益与沪深 300 相比 | | 分析师：张弛 证书编号：S0500525110001 Tel：17621838100 Email：zc08241@xcsc.com 地址：上海市浦东新区银城路88号 中国人寿金融中心10楼 ❑ 首先利好 ...

Group 1: Machinery Industry - In November 2025, sales of construction machinery showed mixed results, with 8 products experiencing year-on-year growth while 4 declined, particularly driven by strong demand for cranes, which saw sales growth of 16.6% for truck cranes, 44.6% for all-terrain cranes, and 66.2% for crawler cranes, largely due to wind power installations and electrification trends [2][3] - Excavator sales in November increased by 13.9% year-on-year, with domestic sales up 9.1% and exports up 18.8%, attributed to recovering demand in Europe and the US, as well as sustained high demand in mining [2][3] - The loader segment also saw significant growth, with total sales up 32.1% year-on-year, driven by replacement demand and electrification, with electric loader penetration reaching approximately 25.7% in November [2][3] - Forklift sales rose by 14.1% year-on-year in November, with domestic sales increasing by 23.9%, primarily due to equipment upgrades and electrification [3] - The outlook for the machinery industry remains positive, with expectations of continued growth in domestic sales driven by major projects and overseas demand from emerging markets and mineral-rich countries [2][3] Group 2: Machine Tool Sector - In November 2025, the production of metal cutting machine tools was approximately 71,000 units, reflecting a year-on-year decline of 2.7%, while cumulative production from January to November reached 783,000 units, showing a year-on-year increase of 12.7% [4][5] - The production of metal forming machine tools in November was about 15,000 units, up 7.1% year-on-year, with cumulative production for the year at 161,000 units, also showing a year-on-year increase of 7.3% [4][5] - Fixed asset investment in the manufacturing sector grew by 1.9% year-on-year, maintaining positive growth, while manufacturing profits increased by 7.7% year-on-year, although the growth rate has slowed [5] Group 3: Robotics Industry - Industrial robot production in November 2025 reached approximately 70,000 units, marking a year-on-year increase of 20.6%, with cumulative production from January to November at 674,000 units, up 29.2% [5] - Strategic partnerships in the robotics sector are emerging, such as the collaboration between UBTECH and Texas Instruments, which aims to enhance the deployment of humanoid robots in manufacturing [5] - The introduction of innovative humanoid robots, such as the TRON 2 by Zhijidongli, showcases advancements in modular design and adaptability for various operational tasks [5] Group 4: Investment Recommendations - The manufacturing PMI in November rose by 0.2 percentage points to 49.2%, indicating a recovery in production and new orders, driven by the end of the National Day holiday effects and positive outcomes from US-China trade talks [6] - The report maintains a "buy" rating for the machinery sector, highlighting the potential for sustained growth in the construction machinery segment and the burgeoning humanoid robotics market [6]

Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.14% this week, ranking 22nd among the 31 primary industries in the Shenwan index [2] - The medical services sub-sector showed a positive performance with a 0.55% increase, while the chemical pharmaceuticals sub-sector declined by 1.74% [2] Industry Performance - The medical services sector's PE (ttm) is 31.74X, and PB (lf) is 3.20X, with a slight increase in both metrics compared to the previous week [5] - Notable performers in the medical services sector include Meinian Health (+24.1%) and Baihua Medicine (+8.8%), while underperformers include Nanhua Biology (-6.5%) and Meidisi (-5.2%) [4] Legislative Impact - The U.S. 2026 National Defense Authorization Act (NDAA) has passed, incorporating the revised Biotech Safety Act, which limits federal contracts with certain biotechnology providers, potentially easing immediate impacts on the domestic biopharmaceutical industry [6][7] - The revised NDAA does not directly name specific companies, which may reduce the immediate shock to the industry [7] Investment Recommendations - The report maintains a "buy" rating for the medical services sector, highlighting high-growth opportunities in ADC CDMO and peptide CDMO companies like WuXi AppTec and Haoyuan Pharmaceutical [8] - It also suggests focusing on companies with expected improvements in profitability, such as Aier Eye Hospital and Dian Diagnostics [8]